Atrial Fibrillation Management Guidelines

Introduction to Atrial Fibrillation Management

The American College of Cardiology states that ivabradine is contraindicated in patients with chronic stable angina and atrial fibrillation due to increased arrhythmia incidence 1

FDA approval is restricted to HFrEF patients (LVEF ≤35%) in sinus rhythm with heart rate ≥70 bpm despite optimal beta-blocker therapy 2, 3
The American College of Cardiology recommends that the drug requires patients to be in sinus rhythm before initiation; while a history of paroxysmal AF is not an absolute contraindication, sinus rhythm must be present at least 40% of the time 1

Beta-blockers are the primary recommendation for rate control in AF, particularly in patients without heart failure or hemodynamic instability 4, 5
Non-dihydropyridine calcium channel blockers (diltiazem, verapamil) are recommended when beta-blockers are inadequate or contraindicated, but only in patients with preserved ejection fraction 4, 5

In HFrEF with AF, beta-blockers and/or digoxin are recommended for rate control 5, 6
Non-dihydropyridine calcium channel blockers are contraindicated (Class III: Harm) in decompensated heart failure or LVEF ≤40% 5, 6

IV amiodarone is the preferred agent for rate control in hypotensive or hemodynamically compromised patients with AF and RVR, as it has a better hemodynamic profile than beta-blockers 7
Urgent electrical cardioversion is indicated for hemodynamically unstable patients 4, 6

If unstable → immediate electrical cardioversion 4, 6
If stable → proceed to evaluate left ventricular function 6
If LVEF >40% → beta-blocker or diltiazem/verapamil 5, 6
If LVEF ≤40% → beta-blocker and/or digoxin (avoid calcium channel blockers) 5, 6
Add digoxin to beta-blocker if inadequate rate control 4, 5
Consider IV amiodarone if other measures fail or are contraindicated 4, 5
AV node ablation with ventricular pacing when pharmacological therapy is insufficient or not tolerated 4, 5

Concurrent use with verapamil or diltiazem is clearly contraindicated as it increases ivabradine exposure and contributes to excessive heart rate lowering 1
Regular cardiac rhythm monitoring is mandatory; discontinue immediately if AF develops 1